"Mitoxantrone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anthracenedione-derived antineoplastic agent.
Below are MeSH descriptors whose meaning is more general than "Mitoxantrone".
Below are MeSH descriptors whose meaning is more specific than "Mitoxantrone".
This graph shows the total number of publications written about "Mitoxantrone" by people in this website by year, and whether "Mitoxantrone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Mitoxantrone" by people in Profiles.
Perl AE, Kasner MT, Shank D, Luger SM, Carroll M. Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res. 2012 Mar 15; 18(6):1716-25.
Ibrahim D, Smith MR, Varterasian M, Karanes C, Millenson M, Yeslow G, Pemberton P, Lai P, Abrams J, Al-Katib A. Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma. Leuk Lymphoma. 2004 Oct; 45(10):2079-84.
Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003 Dec 1; 98(11):2402-9.
Scher HI, Kelly WK. Editorial: States and state transitions are all that really matter. J Urol. 2002 Dec; 168(6):2451-3.